Non-nucleoside reverse transcriptase inhibitors

US8404856B2 · kind B2 · utility

Assignee

• Merck Sharp & Dohme LLC · US

Inventors

• Thomas J. Tucker · North Wales, US
• Robert Tynebor · Hatfield, US
• John T. Sisko · Lansdale, US
• Neville J. Anthony · Hatfield, US
• Robert Gomez · Perkasie, US
• Samson M. Jolly · Collegeville, US

Key dates

• Filing date: Nov 14, 2008
• Grant date: Mar 26, 2013
• Expiry date: Jul 12, 2029

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D471/04
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

Heteroaromatic compounds of Formula (I) are HIV reverse transcriptase inhibitors, wherein ring A is: (ii-a), (ii-b), (ii-c), (ii-d), or (ii-e); and wherein n, L, M, U, X, Y, Z, RE, RF, R1, R2A, R2B, R2C, R3, R8, R9 and R10 are defined herein. The compounds of Formula I and their pharmaceutically acceptable salts and prodrugs are useful in the inhibition of HIV reverse transcriptase, the prophylaxis and treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts and prodrugs can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.